Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

LIGAND PHARMACEUTICALS INC Director's Dealing 2021

Feb 19, 2021

31289_dirs_2021-02-18_ef7fac36-27e9-417f-a33e-78698d80810a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2021-02-15

Reporting Person: FOEHR MATTHEW W (President and COO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-02-15 Common Stock F 641 $172.46 Disposed 167557 Direct
2021-02-15 Common Stock F 1235 $172.46 Disposed 166322 Direct
2021-02-15 Common Stock F 1222 $172.46 Disposed 165100 Direct

Footnotes

F1: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 03/02/2018.

F2: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2019.

F3: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/13/2020.